Jacob sands

Thoracic oncologist, Dana-Farber Cancer Institute. Assistant Professor, Harvard Medical School

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

Check out this recent paper 👉A Longitudinal Comprehensive Biospecimen and Clinical Data Repository for Cancer Early Detection: The InAdvance Study.
🔓https://t.co/tTlFw2yPJ7
✍️@ChowdhuryLab @bdcrompton @NarjustFlorezMD @judygarber5 @IrenemGhobrial @ctdnaMD @ASCOPres @AnnPartridgeMD @sands_jacob @SookbinWoo @g_parmigiani @TimRebbeck @SapnaSyngal @CEBP_AACR

[Jeff Yang MD FACS @ChiFuJeffYang]

I was recently interviewed for this New York Times story by Paula Span on the lifesaving impact of lung cancer screening.

Thank you to Paula for shining a light on this important issue, and to Mr. Dennis Schmidt for sharing your powerful story. Early detection saves lives, and I hope this piece inspires continued efforts to expand awareness of and access to lung cancer screening!

https://t.co/0lIKZqB16C

[PRECISION ONCOLOGY CONNECT powered by COR2ED @PresOnc_Connect]

Test your knowledge!

The evolving TROP2-directed ADC landscape in metastatic #NSCLC 🫁and strategies to optimise the treatment experience

🎓New #lungcancer e-learning from:
Prof. Nicolas Girard (France) @nicogirardcurie
Dr Louise Lim (UK)
Dr Jacob Sands (US) @sands_jacob
Nurse Practitioner Mrs Stephanie McDonald (US)

Learn about:
✔The relevance of TROP2 in metastatic NSCLC

✔Clinical overview of TROP2-directed ADCs in NSCLC, with and without actionable genomic alterations

✔Proactive AE monitoring and management

✔Best practice management

📹 Register to access the module: video, resources + accredited assessment for #CME credit!

>> https://t.co/jZtZf0KGmq

🤝Endorsed by @WarOnCancer, @Exon20Group & @BiomarkerCo

Supported by an Independent Educational Grant from AstraZeneca

#MedEd #Oncology #LCSM #MedTwitter

[COR2ED @COR2EDMedEd]

Test your knowledge!

The evolving TROP2-directed ADC landscape in metastatic #NSCLC 🫁and strategies to optimise the treatment experience

🎓New #lungcancer e-learning from:

Prof. Nicolas Girard (France) @nicogirardcurie
Dr Louise Lim (UK)
Dr Jacob Sands (US) @sands_jacob
Nurse Practitioner Mrs Stephanie McDonald (US)

Learn about:
✔The relevance of TROP2 in metastatic NSCLC

✔Clinical overview of TROP2-directed ADCs in NSCLC, with and without actionable genomic alterations

✔Proactive AE monitoring and management

✔Best practice management

📹 Register to access the module: video, resources + accredited assessment for #CME credit!

>> https://t.co/fcERYmQyoq

🤝Endorsed by @WarOnCancer, @Exon20Group & @BiomarkerCo

Supported by an Independent Educational Grant from AstraZeneca

#MedEd #Oncology #LCSM #MedTwitter

[PeerView @PeerView]

Drs. Nicolas Girard (@nicogirardcurie) and Jacob Sands (@sands_jacob) discuss the latest evidence on TROP2-targeted ADCs in #NSCLC in this new PeerView #MedEd activity. Watch today! https://t.co/y9CBEo7cVQ
#Oncology

[Giannis Mountzios @g_mountzios]

What a happy coincidence!
While presenting intracranial efficacy data from DeLLphi-304 in #ASCO26, #Tarlatamab was officially approved in EU!!

✅ In ITT: CNS mPFS NR vs 7.8 m, HR=0.54
✅ In BM per mRANO: CNS mPFS 6.5 vs 4.2m, HR=0.4
✅ mOS=13.9 vs 6.8, HR=0.51, independent of baseline BM!

A new SoC, hope that all #SCLC patients will soon have access!!

#some #LCSM @OncoAlert @OncBrothers
@OncLive @PortalOnconews @SclcSMASHERS
@myESMO @ASCO @IASCL @PeerView

[Lauren Averett Byers, MD @LaurenByersMD]

Check out the full manuscript published online during the oral abstract @NatureMedicine @UTMDAnderson @ASCO @IASLC

[OncLive.com @OncLive]

SCLC is no longer a one-size-fits-all disease. @sands_jacob, of @DanaFarber, maps the full evolving landscape in the latest #OncLiveOnAir episode. #lcsm

🎧 Listen: https://t.co/VgtMsrmkoe

[Laura Alder, MD @LauraAlderMD]

DLL3-🛡️CAR-T for SCLC is here! #ASCO26 | LB2102 Phase 1 (n=20) — Dr. Zhonglin Hao et al.
✅ No DLTs · No deaths
📊 ORR 27% · DCR 91%
⏳ Median DOR 208 days !
📈 Higher CAR-T expansion → better response
Dose optimization could unlock even more activity.
#LCSM @sands_jacob @BalazsHalmosMD @BenCreelan

[Jacob sands @sands_jacob]

I'm excited to be co-hosting ASCO discussions on Roon, a physicians-only social platform where I'll be sharing in real time throughout the conference. Whether you're attending the conference or following from home, come join me! Link: https://t.co/8lGcmRFa8t

[Roon Doctors @roondoctors]

Meet your #ASCO2026 co-hosts on Roon! These leaders in hematology and oncology are sharing their takeaways, questions, and highlights from this year's conference — and they're already discussing what they're most anticipating.

A huge thank you to our co-hosts from our founding physician community for leading the conversation: @aparna1024, @chadinabhan, @christinemphmd, @DrDanaChase, Don Dizon, @GlopesMd, @HannahRAbrams, @hoperugo, @sands_jacob, @DrKarineTawagi, @LesleyWu22, @l_schapira, @docbraunstein, Mercedes Castiel, @PTarantinoMD, @RMiksad, and Sunandana Chandra.

Why follow ASCO 2026 on Roon? Roon is a social platform for physicians only. No algorithms deciding what you see, no important research takeaways getting buried. Just evidence-based discourse reminiscent of the MedTwitter days.

Join the conversation: https://t.co/Rit17QYxgB

[OncLive.com @OncLive]

New insights on EGFR+ NSCLC! Jacob Sands, MD, Heather Wakelee, MD, and Alissa J. Cooper, MD break down how to interpret efficacy outcomes (PFS & OS), biomarker testing, and the emerging role of TROP2-directed ADCs to guide individualized patient care.

Watch the series: https://t.co/CL5exAT4sg

@sands_jacob @DanaFarber @HwakeleeMD @StanfordMed @alissajcooper

[LUNG CONNECT powered by COR2ED @lung_connect]

📢 Still time to register! 📢

Sign up for our virtual Experts Knowledge Share interactive webinar, hosted by renowned medical experts

“The evolving TROP2-directed ADC landscape in metastatic #NSCLC, and strategies to optimise the treatment experience”

🗓️ This Monday, 11th May 2026
🕜 11:30 EDT | 16:30 BST | 17:30 CEST

Register now: https://t.co/uRZpsQrA3y

Topics include:
✔️ The relevance of TROP2 in metastatic NSCLC
✔️ Clinical overview of TROP2-directed ADCs in NSCLC:
--> Pre-treated advanced/mNSCLC
--> Ongoing 1st line advanced/mNSCLC
✔ Proactive AE monitoring and management
✔️ Best practice management: panel discussion and audience questions

Scientific Committee:
Prof. Nicolas Girard (France) @nicogirardcurie
Dr Louise Lim (UK)
Dr Jacob Sands (US) @sands_jacob
Nurse Practitioner Stephanie McDonald (US)

Supported by an Independent Educational Grant from AstraZeneca. This event is for HCPs only.

#MedTwitter #MedEd #OncTwitter🎬

[Oncology Brothers @OncBrothers]

This is the treatment algorithm we’ve used during our discussion with @sands_jacob for Small Cell Lung Cancer!

✅ Limited Stage
✅ Extensive Stage
✅ Supportive care w/ Lurbi & Access around Tarla

#OncTwitter #MedX @OncUpdates #lcsm @OncoAlert

[Jacob sands @sands_jacob]

https://t.co/954qHrB2Ec

[Misty Dawn Shields @drshieldsmd]

The fourth annual Texas Lung Cancer Conference LIVE from @acllive was fabulous! Thank you to Dr. Stephen Liu @StephenVLiu & Dr. Tina Cascone for the invitation and the wonderful @IDEOlogyHealth team as such fantastic hosts! Grateful for a thoracic oncology community that is TRULY family! #sclc #nsclc #meded #lungcancer

@lungoncdoc @sands_jacob @ErinGillaspie @IyengarPuneeth @WadeIams @NaglaAKarimMD @teekayowo @NouraChoudhury @RManochakian @LUNGevity

[PER @gotoPER]

🫁Stay up to date on emerging therapies in SCLC with experts @sands_jacob & @Annechiangmd!

Explore the mechanisms behind DLL3-targeting T-cell engagers, review the latest trial evidence, and learn how to safely integrate these approaches into practice.

🔗https://t.co/EiZgb7EVAC

[TLC Conference @TLCconference]

Tackling the toughest cases in lung cancer — from small-cell transformation and NUT carcinoma to brain mets in driver-negative NSCLC and beyond. The Clinical Challenges session at #TexasLung26 is moderated by Dr. @sands_jacob and features an all-star panel: Drs. Carl Gay, Paul Paik, Sarah Goldberg, Melissa Crawley, @LealTiciana, @JhanelleGray, and Andrew Shaw. Don't miss the 2-Day CE-Accredited conference! Check out the full agenda and register for FREE today with code FREECME: https://t.co/szwccXu59K
April 9–11 | ACL Live, Austin, TX #ThoracicOncology #LungCancer #MedEd

[David Gandara @drgandara]

Results of OSI plus DATODXD after PD on OSI are worth pursuing. Nice results although a small study. Needs confirmation.

[IDEOlogy Health @IDEOlogyHealth]

IDEO Xchange: In DeLLphi‑304, tarlatamab beat chemo in 2L SCLC(OS 13.6 vs 8.3 mo; HR 0.60) with mostly low‑grade CRS/ICANS—but requires early monitoring infrastructure. Should it be immediate 2L SOC?